Health & Medicinearticle2026-11-13

Critical Assessments of Computational Hit-finding Experiments Challenge #4: Targeting the Tyrosine Kinase Binding Domain of the E3 Ligase Casitas B-Lineage Lymphoma Proto-Oncogene B, an Immuno-Oncology Target

Open access0 citations

Abstract

Abstract The critical assessments of computational hit-finding experiments (CACHE) are prospective benchmarking exercises where small molecule ligands predicted for a nominated protein of interest are procured and tested experimentally. In CACHE #4, 23 participating teams each selected up to 100 compounds designed to bind the E3 ligase CBLB, an immuno-oncology target. The organizers released the first public structure of CBLB in complex with a known ligand at the outset of the challenge to enable the discovery of chemically novel molecules. Out of the 1688 compounds collectively predicted, ten compounds from nine participants showed some sign of activity (primary hits), but only two were convincingly confirmed (validated hits) across multiple biophysical binding assays and in subsequent analogs, and only one of them was chemically novel. The apparent difficulty of finding novel CBLB ligands, previously reflected by the chemical similarity of inhibitors from the patent literature, suggests that potent CBLB hit molecules were either rare in the screened commercial libraries, or that computational methods may have struggled to retrieve presumably present but weak ligands, or that the conformational dynamics of the binding site was not sufficiently accounted for. The successful method was strikingly atypical. Selection from a chemical binding similarity classifier followed by a random forest binding affinity predictor trained on inhibitors from the patent literature was refined using a diffusion-model binding pose predictor. The road to an ML-driven breakthrough in computational hit-finding can take unexpected turns. Which of these turns reveal novel horizons and which are mere distractions will best be investigated and answered collectively. The discovery in CACHE #4 of a novel series of CBLB ligands is not a trivial achievement and may inform medicinal chemistry efforts toward clinical candidates that complement immune checkpoint inhibition to elicit antitumor immune response in cancer patients.

// Source

View paper (DOI)Open access versionOpenAlexJournal of Chemical Information and ModelingPublished 2026-11-13

Authors: Madhushika Silva, Oleksandra Herasymenko, Abd Al‐Aziz A. Abu‐Saleh, Suzanne Z. Ackloo, Rima Al‐awar, C.H. Arrowsmith, Ryota Ashizawa, David J. Bearss, Beck Hartmut, Kevin P. Bishop, Vincent Blay, Hugo J. Bohórquez, Albina Bolotokova, Duanhua Cao, Irene Chau, Lin Chen, Sandro Cosconati, Wim Dehaen, Kristina Edfeldt, Elisa Gibson, Gediminas Gumbis, Christoph Gorgulla, Anders Gunnarsson, Rachel J. Harding, Laurent Hoffer, Anders Hogner, Douglas R. Houston, Oleksii Hrabovskyi, John J. Irwin, Diane Joseph‐McCarthy, Andrea Karlova, Sergei Kotelnikov, Dima Kozakov, Uta F. Lessel, Peter Loppnau, Wei Lu, Kyle Medley, Miles McGibbon, Yurii Moroz, Charuvaka Muvva, Benito Natale, Boyang Ni, Eva Nittinger, Tudor Ionel Oprea, Brooks Paige, Keunwan Park, Gennady Poda, Konstantin Popov, Mykola Protopopov, Vera Pütter, Edina Rosta, Michele Roggia, Yogesh Sabnis, Christopher Secker, Olha Semenenko, Conrad Veranso Simoben, Olga O. Tarkhanova, Dakota Treleaven, Alexander Tropsha, David Uehling, Hariprasad Vankayalapati, Jude Wells, James Wellnitz, Yvonne Westermaier, Lars Wortmann, Jie Yu, J C Zhang, Runze Zhang, Mingyue Zheng, Shuangjia Zheng, Yuchen Zhou, Sara Ziadat, Levon Halabelian, Matthieu Schapira

Institutions: Chinese Academy of Sciences, Karolinska Institutet, Harvard University, University of North Carolina at Chapel Hill, University of California, San Francisco, University of Toronto, Boston University, University Health Network, University College London, Bayer (Germany), Karolinska University Hospital, University of Edinburgh, The University of Texas at Austin, Massachusetts Institute of Technology, University of Chemistry and Technology, Prague, University of California, Santa Cruz, Princess Margaret Cancer Centre, Korean Association Of Science and Technology Studies, Korea Institute of Science and Technology, University of Campania "Luigi Vanvitelli", Taras Shevchenko National University of Kyiv, St. Jude Children's Research Hospital, BioNTech (United States), Boehringer Ingelheim (Austria), Boehringer Ingelheim (Germany), Zuse Institute Berlin, Ontario Institute for Cancer Research, AstraZeneca (United Kingdom), Palladin Institute of Biochemistry, Enamine (Ukraine), Structural Genomics Consortium